To provide a method for judging recurrence risk of hepatocarcinoma using biomarkers that can accurately judge the recurrence risk of hepatocarcinoma, and to provide a kit for judging the recurrence risk of hepatocarcinoma.
By using 7 genes (CYP2A6, SLC10A1, SLC22A1, ESR1, GLYAT, TSPAN8 and NQO1) as the biomarkers, the recurrence risk of hepatocarcinoma can be judged (predicted) accurately. When 3 biomarker genes (SLC22A1, TSPAN8 and NQO1) selected from 7 biomarker genes are used with further COL15A1 and ABCB6 genes as the biomarkers to carry out discriminant analysis, 88% (sensitivity) of the patients that suffer from recurrence 2 years after the operation are judged as "hepatocarcinoma will recur within 2 years after the surgery", and 100% (specificity) of the patients having no hepatocarcinoma recurrence over 2 years after the operation are judged as "hepatocarcinoma will not recur over 2 years after the operation". Thus the recurrence risk of hepatocarcinoma can be judged with high accuracy.
OKA MASAO
| JP2006526405A | 2006-11-24 | |||
| JP2011501962A | 2011-01-20 | |||
| JP2009517064A | 2009-04-30 |
| WO2007058623A1 | 2007-05-24 | |||
| WO2010100899A1 | 2010-09-10 | |||
| WO2011068839A1 | 2011-06-09 |
JPN6016024625; ＢＭＣ Ｃａｎｃｅｒ ２０１２， １２：１０９ , 20120322
JPN6016024626; Ｊｏｕｒｎａｌ ｏｆ Ｈｅｐａｔｏｌｏｇｙ Ｖｏｌ． ３５, 2001, ｐｐ．６３７-６４２
Seiji Ozawa
Yusaku Tokai
High Kazuya Tsu
Makoto Horiuchi